Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.

[1]  S. Söderberg,et al.  A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension , 2018, European heart journal.

[2]  R. Benza,et al.  Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials? , 2018, American journal of respiratory and critical care medicine.

[3]  R. Benza,et al.  Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it , 2018 .

[4]  A. Torbicki,et al.  Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. , 2018, Journal of the American College of Cardiology.

[5]  M. Humbert,et al.  The Low‐Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal‐oriented Clinical Trial Endpoints? , 2017, American journal of respiratory and critical care medicine.

[6]  S. Rosenkranz,et al.  REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  H. Ghofrani,et al.  REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  R. Benza,et al.  Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  M. Humbert,et al.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.

[10]  S. Rosenkranz,et al.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.

[11]  M. Humbert,et al.  Epidemiology and treatment of pulmonary arterial hypertension , 2017, Nature Reviews Cardiology.

[12]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[13]  R. Benza,et al.  Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.

[14]  Michael J Pencina,et al.  Evaluating Discrimination of Risk Prediction Models: The C Statistic. , 2015, JAMA.

[15]  M. Humbert,et al.  Validation of two predictive models for survival in pulmonary arterial hypertension , 2015, European Respiratory Journal.

[16]  R. Benza,et al.  Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  M. Mcgoon,et al.  Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry , 2014, Chest.

[18]  R. Benza,et al.  Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. , 2013, Chest.

[19]  Karl Swedberg,et al.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.

[20]  J. Lordan,et al.  Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. , 2012, American journal of respiratory and critical care medicine.

[21]  R. Benza,et al.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.

[22]  A. Peacock,et al.  Predicting survival in pulmonary arterial hypertension in the UK , 2012, European Respiratory Journal.

[23]  R. Dweik,et al.  Portopulmonary hypertension: a report from the US-based REVEAL Registry. , 2012, Chest.

[24]  M. Gomberg-Maitland,et al.  Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. , 2012, Chest.

[25]  J. Barberà,et al.  Survival in pulmonary hypertension in Spain: insights from the Spanish registry , 2012, European Respiratory Journal.

[26]  R. Benza,et al.  The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. , 2012, Chest.

[27]  A. Denault,et al.  Characteristics and Outcome After Hospitalization for Acute Right Heart Failure in Patients With Pulmonary Arterial Hypertension , 2011, Circulation. Heart failure.

[28]  J. Wild,et al.  ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre , 2011, European Respiratory Journal.

[29]  M. Mcgoon,et al.  Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. , 2011, Chest.

[30]  Dave P. Miller,et al.  Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. , 2010, Chest.

[31]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[32]  M. Humbert,et al.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.

[33]  E. Antman,et al.  Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. , 2009, American heart journal.

[34]  G. Raskob,et al.  Design of the REVEAL registry for US patients with pulmonary arterial hypertension. , 2008, Mayo Clinic proceedings.

[35]  Sanjiv J. Shah,et al.  Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension , 2008, Circulation.

[36]  M. Grabowski,et al.  Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty. , 2007, International journal of cardiology.

[37]  E. Antman,et al.  TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.

[38]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .